SPPH :
He is currently teaching and lecturing at the Institute of Biomedical Engineering (Department of Chemical Engineering) at Ecole Polytechnique de Montreal since 2007 as a senior scientist where he currently manages a suite of molecular and cell biology laboratories.
"Dr. Merzouki is a molecular biologist and an immunologist with a long experience in the gene therapy area where he has performed several preclinical and clinical analysis for pharmaceutical companies involving the use of adenoviral vectors for cancer (Introgen Therapeutics Inc., USA Gencell Asia/Pacific, Japan) and DNA plasmid vectors for peripheral artery occlusive disease (Aventis Pharma, France/USA). Dr. Merzouki has an extensive expertise in the design of expressing vectors, production and purification of recombinants proteins. He developed technologies (Patents pending) for production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis," stated Dr. Max Arella, CEO and Chairman of Spencer Pharmaceutical Inc. "We are pleased that Dr. Merzouki has accepted to serve Spencer Pharmaceutical as a scientific and business advisor. His extensive network in scientific and businesses circles in the Middle East/North Africa regions will certainly be a major asset for our company in future negotiations in this part of the world," concluded Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
AI
